Lung Cancer Prognosis Genetic Analysis Kit

Eight Genes SNP Multiplex Genotyping Kit (EGSM7500-48T)

Genetic Testing Reagent for Tumors, Grade 3

Features

Subject to inspection	Principle	Clinical Sample	Inspection method	Test Type
Surgical patients with early-stage non-small cell lung cancer (NSCLC)	Amplification of 8 specific SNP regions to determine genotypes	Whole genome extracted from whole blood	Real-time Chain RPolymerase eaction (Real-time PCR)	Qualitative Test

- Compatible with AB7500 Real time PCR
- Interpretation: High&Low Risk
- Saves time and cost compared to Sanger Sequencing
- Screening patients at high risk for lung cancer recurrence
- Provide information to assist in formulating treatment strategies

Components



Product Configuration (48 tests)

1. 4X SNP Genotyping Assay EGSMX (X : 1~8)
2. Positive Control DNA Allele1/1 (1W~8W)
3. Positive Control DNA Allele1/2 (1H~8H)
4. Positive Control DNA Allele2/2 (1M~8M)
5. Nuclease Free Water
6. 2X PCR Master Mix

Necessity

- Lung cancer is difficult to detect early because it often does not cause noticeable symptoms in its initial stages. By the time it is diagnosed, it has often already metastasized to other parts of the body.
- Lung cancer has a relatively high mortality rate, with an average 5-year survival rate of only about 20%.
- In particular, non-small cell lung cancer (NSCLC) presents varying risks of recurrence and mortality even among patients at the same pathological stage after surgery.
- To ensure effective postoperative treatment and supportive care, the importance of biomarkers for accurately assessing individual lung cancer prognoses is increasing.
- Based on extensive research, D&P Biotech has identified eight markers with strong correlations to NSCLC prognosis and developed a lung cancer prognosis gene analysis kit capable of simultaneously detecting multiple markers.

Leading Causes of Cancer Mortality Worldwide

Bronchial & Lung Cancer	1	Breast Cancer
Oropharyngeal Cancer	2	Bronchial & Lung Cancer
Liver Cancer	3	Stomach Cancer
Colorectal Cancer	4	Colorectal Cancer
Esophageal Cancer	5	Cervical Cancer
Prostate Cancer	6	Liver Cancer
Oropharyngeal Cancer	7	Esophageal Cancer
Lymphoma & Multiple Myeloma	8	Ovarian Cancer
Leukemia	9	Lymphoma & Multiple Myeloma
Bladder Cancer	10	Pancreatic Cancer

Comparison with Competitors

Comparison of 5-Year Survival Rates Between Our Product and Company M's Product





Our lung cancer prognosis gene analysis kit demonstrates superior statistical power compared to competitors